Yazar "Kocar, Muharrem" seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology(Springer, 2014) Gumusay, Ozge; Coskun, Ugur; Akman, Tulay; Ekinci, Ahmet Siyar; Kocar, Muharrem; Erceleb, Ozlem Balvan; Yazici, OzanThe development of brain metastases (BMs) was associated with poor prognosis in melanoma patients. Patients with BMs have a median survival of < 6 months. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10-40 %. Our aim was to identify factors predicting development of BMs and survival. We performed a retrospective analysis of 470 melanoma patients between 2000 and 2012. The logistic regression analyses were used to identify the clinicopathological features of primary melanoma that are predictive of BMs development and survival after a diagnosis of brain metastases. There were 52 patients (11.1 %) who developed melanoma BMs during the study period. The analysis of post-BMs with Kaplan-Meier curves has resulted in a median survival rate of 4.1 months (range 2.9-5.1 months). On logistic regression analysis site of the primary tumor on the head and neck (p = 0.002), primary tumor thickness (Breslow > 4 mm) (p = 0.008), ulceration (p = 0.007), and pathologically N2 and N3 diseases (p = 0.001) were found to be significantly associated with the development of BMs. In univariate analysis, tumor thickness and performance status had a significant influence on post-BMs survival. In multivariate analysis, these clinicopathologic factors were not remained as significant predictive factors. Our results revealed the importance of primary tumor characteristics associated with the development of BMs. Ulceration, primary tumor thickness, anatomic site, and pathologic a parts per thousand yenN2 disease were found to be significant predictors of BMs development.Öğe Sunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Turkish Oncology Group Trial(Int Inst Anticancer Research, 2014) Yildiz, Ibrahim; Ekenel, Meltem; Akman, Tulay; Kocar, Muharrem; Uysal, Mukremin; Kanitez, Metin; Varol, UmutAim: This study aimed to assess the clinical efficacy and toxicity of sunitinib, a targeted-agent, for non-clear cell renal cell carcinoma. Patients and Methods: Sixty-three patients with complete clinical data from 13 oncology Centers were retrospectively evaluated. Outcomes analyzed were objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and adverse events. Results: The median age of all patients, 38 men (60.3%) and 25 women (39.7%), was 63 years (range=25-82 years). Histological subtypes included 46 (88%) cases of papillary RCC, 10 of chromophobe, and 7 unclassified cases. Median treatment duration was seven months (range=2-86 months). At the time of this analysis, 52 patients had discontinued treatment, 33 of whom had died. Treatment discontinuation was due to disease progression in 43 patients, and toxicity in nine. Dose interruption was necessary in 22 (34.9%) patients, and dose reduction in 27 (42.9%). The objective response rate and disease control rate were 11.1% and 63.5%, respectively. The median PFS and OS were 7.6 months (95% confidence interval (CI)=5.5-9.7 months) and 22.0 months (95% CI=13.4-30.6 months), respectively, with 1-year rates of 64.7% and 33.7%, respectively. Conclusion: Clinical outcome of the metastatic non-clear cell RCC patients with sunitinib treatment seemed to be worse than the historical data of clear cell RCC patients, in terms of PFS, OS and objective response. New and more effective targeted-therapies and better understanding of the underlying molecular processes are necessary to improve survival outcome for these patients.Öğe Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retpospective Turkish Oncology Group (TOG) trial.(Lippincott Williams & Wilkins, 2014) Yildiz, Ibrahim; Ekenel, Meltem; Altman, Tuley; Kocar, Muharrem; Uysal, Mukremin; Kanitez, Metin; Bayoglu, Vedat[Abstract Not Available]
